# A Trial of Selinexor, Ruxolitinib and Methylprednisolone

> **NCT06225310** · PHASE1 · RECRUITING · sponsor: **Oncotherapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Ruxolitinib
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT06225310
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225310, "A Trial of Selinexor, Ruxolitinib and Methylprednisolone". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06225310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*